BR112013008615A2 - formulação farmacêutica para inibidores de desacetilase de histona - Google Patents
formulação farmacêutica para inibidores de desacetilase de histonaInfo
- Publication number
- BR112013008615A2 BR112013008615A2 BR112013008615A BR112013008615A BR112013008615A2 BR 112013008615 A2 BR112013008615 A2 BR 112013008615A2 BR 112013008615 A BR112013008615 A BR 112013008615A BR 112013008615 A BR112013008615 A BR 112013008615A BR 112013008615 A2 BR112013008615 A2 BR 112013008615A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulation
- histone deacetylase
- deacetylase inhibitors
- inhibitors
- histone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39285510P | 2010-10-13 | 2010-10-13 | |
| US61/392,855 | 2010-10-13 | ||
| PCT/US2011/056148 WO2012051416A1 (en) | 2010-10-13 | 2011-10-13 | Pharmaceutical formulation for histone deacetylase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013008615A2 true BR112013008615A2 (pt) | 2016-06-14 |
| BR112013008615B1 BR112013008615B1 (pt) | 2021-05-11 |
Family
ID=44903378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013008615-7A BR112013008615B1 (pt) | 2010-10-13 | 2011-10-13 | composição farmacêutica |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US9255066B2 (pt) |
| EP (1) | EP2627316B1 (pt) |
| JP (2) | JP6025732B2 (pt) |
| CN (1) | CN103347498B (pt) |
| BR (1) | BR112013008615B1 (pt) |
| CA (1) | CA2814696C (pt) |
| CY (1) | CY1121655T1 (pt) |
| HR (1) | HRP20191068T1 (pt) |
| MX (1) | MX342041B (pt) |
| PT (1) | PT2627316T (pt) |
| RS (1) | RS58895B1 (pt) |
| RU (1) | RU2625758C2 (pt) |
| SI (1) | SI2627316T1 (pt) |
| WO (1) | WO2012051416A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106714794B (zh) * | 2014-05-13 | 2021-05-11 | 登卓药物有限公司 | 用于治疗甲状腺功能亢进的制剂 |
| WO2016134130A1 (en) * | 2015-02-20 | 2016-08-25 | Pedicis Research Llc | Compositions and methods for treatment of skin infections |
| KR20210124310A (ko) | 2019-02-06 | 2021-10-14 | 벤테라, 인코포레이티드 | 국소 포스포이노시티드 3-키나제 억제제 |
| WO2020231800A1 (en) * | 2019-05-10 | 2020-11-19 | Encube Ethicals Private Limited | Topical antifungal formulation |
| EP4192431A1 (en) * | 2020-08-04 | 2023-06-14 | Venthera, Inc. | Formulations of phosphoinositide 3-kinase inhibitors |
| CN115737549A (zh) * | 2022-11-24 | 2023-03-07 | 北京鑫开元医药科技有限公司 | 一种具有hdac抑制活性的注射液及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110697A (en) | 1995-09-20 | 2000-08-29 | Merck & Co., Inc. | Histone deacetylase as target for antiprotozoal agents |
| US6387673B1 (en) | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
| US6376508B1 (en) | 2000-12-13 | 2002-04-23 | Academia Sinica | Treatments for spinal muscular atrophy |
| US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| AU2002348474A1 (en) | 2001-10-18 | 2003-04-28 | The Salk Institute For Biological Studies | Methods of using deacetylase inhibitors to promote cell differentiation and regeneration |
| US6809118B2 (en) | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
| US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| UA89035C2 (ru) * | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| EP1924245A2 (en) | 2005-08-19 | 2008-05-28 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Topical formulations of histone deacetylase inhibitors and methods of using the same |
| BRPI0707826B1 (pt) | 2006-02-14 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Compostos inibidores de histona desacetilase, composição farmacêutica e uso dos referidos compostos |
-
2011
- 2011-10-13 CA CA2814696A patent/CA2814696C/en active Active
- 2011-10-13 BR BR112013008615-7A patent/BR112013008615B1/pt active IP Right Grant
- 2011-10-13 RU RU2013120914A patent/RU2625758C2/ru active
- 2011-10-13 EP EP11776958.8A patent/EP2627316B1/en active Active
- 2011-10-13 SI SI201131720T patent/SI2627316T1/sl unknown
- 2011-10-13 RS RS20190762A patent/RS58895B1/sr unknown
- 2011-10-13 PT PT11776958T patent/PT2627316T/pt unknown
- 2011-10-13 JP JP2013534005A patent/JP6025732B2/ja active Active
- 2011-10-13 CN CN201180059246.0A patent/CN103347498B/zh active Active
- 2011-10-13 WO PCT/US2011/056148 patent/WO2012051416A1/en active Application Filing
- 2011-10-13 MX MX2013004117A patent/MX342041B/es active IP Right Grant
- 2011-10-13 US US13/878,994 patent/US9255066B2/en active Active
-
2015
- 2015-12-30 US US14/983,761 patent/US20160106700A1/en not_active Abandoned
-
2016
- 2016-08-10 JP JP2016158040A patent/JP2016188261A/ja not_active Withdrawn
-
2017
- 2017-06-29 US US15/637,979 patent/US10258595B2/en active Active
-
2019
- 2019-02-14 US US16/275,395 patent/US20190175539A1/en not_active Abandoned
- 2019-05-24 CY CY20191100555T patent/CY1121655T1/el unknown
- 2019-06-13 HR HRP20191068TT patent/HRP20191068T1/hr unknown
-
2020
- 2020-07-09 US US16/924,591 patent/US11607399B2/en active Active
-
2023
- 2023-02-08 US US18/107,179 patent/US20230190696A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI2627316T1 (sl) | 2019-06-28 |
| WO2012051416A1 (en) | 2012-04-19 |
| US20190175539A1 (en) | 2019-06-13 |
| US9255066B2 (en) | 2016-02-09 |
| EP2627316B1 (en) | 2019-03-27 |
| EP2627316A1 (en) | 2013-08-21 |
| MX2013004117A (es) | 2013-12-02 |
| RU2625758C2 (ru) | 2017-07-18 |
| US20210038555A1 (en) | 2021-02-11 |
| US11607399B2 (en) | 2023-03-21 |
| CN103347498B (zh) | 2016-04-13 |
| PT2627316T (pt) | 2019-06-11 |
| CA2814696A1 (en) | 2012-04-19 |
| CY1121655T1 (el) | 2020-07-31 |
| US10258595B2 (en) | 2019-04-16 |
| US20130203847A1 (en) | 2013-08-08 |
| MX342041B (es) | 2016-09-12 |
| US20170360741A1 (en) | 2017-12-21 |
| US20230190696A1 (en) | 2023-06-22 |
| CA2814696C (en) | 2019-03-12 |
| BR112013008615B1 (pt) | 2021-05-11 |
| HRP20191068T1 (hr) | 2019-09-06 |
| RS58895B1 (sr) | 2019-08-30 |
| RU2013120914A (ru) | 2014-11-20 |
| CN103347498A (zh) | 2013-10-09 |
| JP6025732B2 (ja) | 2016-11-16 |
| JP2016188261A (ja) | 2016-11-04 |
| US20160106700A1 (en) | 2016-04-21 |
| JP2013539793A (ja) | 2013-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014009932A2 (pt) | derivados de hidroxamato para inibidores da hdac e composição farmacêutica contendo os mesmos | |
| HRP20181381T1 (hr) | Novi inhibitori histon deacetilaze | |
| IL280820A (en) | Histone deacetylase inhibitors | |
| EP2701699A4 (en) | INHIBITORS OF HISTONE DEACETYLASE | |
| EP2680694A4 (en) | INHIBITORS OF HISTONE DEACETYLASE | |
| HRP20181965T1 (hr) | Novi derivati azaindola kao selektivni inhibitori histonske deacetilaze (hdac) i farmaceutski pripravci koji ih sadrže | |
| EP3055299A4 (en) | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors | |
| BRPI0817860A2 (pt) | inibidores de histona deacetilase | |
| EP2836484A4 (en) | HISTONE DEACETYLASE INHIBITORS (HDAC) | |
| BR112012030193A2 (pt) | compostos macrocíclicos úteis como inibidores de histona desacetilases | |
| EP2451790A4 (en) | INHIBITORS OF HISTONE DEACETYLASE | |
| BR112012026686A2 (pt) | fórmulas melhoradas para dispositivos médicos revestidos com droga | |
| IL227379A0 (en) | Histone deacetylase inhibitors and compositions and methods of using them | |
| HK1200809A1 (en) | Cinnamic acid hydroxyamides as inhibitors of histone deacetylase | |
| BR112013008615A2 (pt) | formulação farmacêutica para inibidores de desacetilase de histona | |
| IL236686A0 (en) | Inhibitors of histone deacetylase and compositions and methods of using them | |
| HK1204998A1 (en) | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof | |
| BRPI0821247A2 (pt) | Inibidores de histona deacetilase | |
| HK1220406A1 (zh) | 組蛋白去乙酰酶抑制劑及組合物 | |
| DK2654813T3 (da) | Sprøjtebare farmaceutiske sammensætninger til topisk anvendelse omfattende sucralfatgel | |
| ES1076221Y (es) | Plataforma para lugares de dificil acceso | |
| HK1160443A1 (en) | Histone deacetylase inhibitors | |
| FI20105854A0 (fi) | Farmaseuttiset eläinlääkekoostumukset |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: TETRALOGIC SHAPE UK LTD (GB) |
|
| B25A | Requested transfer of rights approved |
Owner name: TETRALOGIC SHAPE UK LTD (GB) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B25G | Requested change of headquarter approved |
Owner name: TETRALOGIC SHAPE UK LTD (GB) |
|
| B25A | Requested transfer of rights approved |
Owner name: MEDVIR AB (SE) |
|
| B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: MEDIVIR AB (SE) Free format text: RETIFICACAO DO DESPACHO (25.1) TRANSFERENCIA DE TITULAR PUBLICADO NA RPI NO 2529, DE 25/06/2019, QUANTO AO ITEM (71) : DEPOSITANTE.ONDE SE LE: MEDVIR ABLEIA-SE: MEDIVIR AB |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2011, OBSERVADAS AS CONDICOES LEGAIS. |